JP2006521088A - 抗活性化ｒａｓ抗体 - Google Patents

抗活性化ｒａｓ抗体 Download PDF

Info

Publication number
JP2006521088A
JP2006521088A JP2004570301A JP2004570301A JP2006521088A JP 2006521088 A JP2006521088 A JP 2006521088A JP 2004570301 A JP2004570301 A JP 2004570301A JP 2004570301 A JP2004570301 A JP 2004570301A JP 2006521088 A JP2006521088 A JP 2006521088A
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence
ras
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004570301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006521088A5 (cg-RX-API-DMAC10.html
Inventor
ラビッツ，テレンス，ハワード
智之 田中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0226723A external-priority patent/GB0226723D0/en
Priority claimed from GBGB0226729.2A external-priority patent/GB0226729D0/en
Priority claimed from GB0226728A external-priority patent/GB0226728D0/en
Priority claimed from GBGB0226727.6A external-priority patent/GB0226727D0/en
Priority claimed from GB0226731A external-priority patent/GB0226731D0/en
Priority claimed from GB0316680A external-priority patent/GB0316680D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of JP2006521088A publication Critical patent/JP2006521088A/ja
Publication of JP2006521088A5 publication Critical patent/JP2006521088A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2004570301A 2002-11-15 2003-11-14 抗活性化ｒａｓ抗体 Withdrawn JP2006521088A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0226723A GB0226723D0 (en) 2002-11-15 2002-11-15 Antibodies for in vitro use
GBGB0226729.2A GB0226729D0 (en) 2002-11-15 2002-11-15 Intracellular antibodies
GB0226728A GB0226728D0 (en) 2002-11-15 2002-11-15 Anti-activated RAS antibodies
GBGB0226727.6A GB0226727D0 (en) 2002-11-15 2002-11-15 Intrabodies
GB0226731A GB0226731D0 (en) 2002-11-15 2002-11-15 Method for generating immunoglobulin genes
GB0316680A GB0316680D0 (en) 2003-07-16 2003-07-16 Anti-activated RAS antibodies
PCT/GB2003/004953 WO2004046188A2 (en) 2002-11-15 2003-11-14 Anti-activated ras antibodies

Publications (2)

Publication Number Publication Date
JP2006521088A true JP2006521088A (ja) 2006-09-21
JP2006521088A5 JP2006521088A5 (cg-RX-API-DMAC10.html) 2006-11-30

Family

ID=32330172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004570301A Withdrawn JP2006521088A (ja) 2002-11-15 2003-11-14 抗活性化ｒａｓ抗体

Country Status (6)

Country Link
US (1) US20050288492A1 (cg-RX-API-DMAC10.html)
EP (1) EP1565495A2 (cg-RX-API-DMAC10.html)
JP (1) JP2006521088A (cg-RX-API-DMAC10.html)
AU (1) AU2003282247A1 (cg-RX-API-DMAC10.html)
CA (1) CA2506128A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004046188A2 (cg-RX-API-DMAC10.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8532164B2 (en) 2008-03-12 2013-09-10 Panasonic Corporation Wireless communication apparatus, wireless communication system, and wireless communication method
JP2017529870A (ja) * 2014-07-22 2017-10-12 オルム セラピューティクス インコーポレイテッドＯｒｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 完全型免疫グロブリン形態の細胞質浸透能を有する抗体を利用して細胞内活性化されたｒａｓを抑制する方法及びその利用
US10787487B2 (en) 2018-06-21 2020-09-29 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies
US10844136B2 (en) 2014-07-22 2020-11-24 Orum Therapeutics Inc. Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
US11155641B2 (en) 2016-05-27 2021-10-26 Orum Therapeutics Inc. Cytosol-penetrating antibody and use thereof
JP2023525164A (ja) * 2020-05-12 2023-06-14 オックスフォード・ユニバーシティ・イノベイション・リミテッド 標的特異的分解剤及びそれらの医学的使用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2360255E (pt) 2005-03-25 2015-04-08 Nat Res Council Canada Método para isolamento de polipéptidos solúveis
EP1867661A1 (en) * 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
AU2010238346A1 (en) * 2009-04-14 2011-11-03 Trojan Technologies Ltd. Therapeutic Antennapedia-antibody molecules and methods of use thereof
GB201103631D0 (en) * 2011-03-03 2011-04-13 Univ Leeds Identification of candidate therapeutics
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
WO2016013871A1 (ko) * 2014-07-22 2016-01-28 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
WO2019014190A1 (en) 2017-07-10 2019-01-17 Brown Kathlynn C MOLECULAR GUIDANCE SYSTEM PEPTIDES AND USES THEREOF
EP3652195A4 (en) 2017-07-10 2021-08-04 SRI International PEPTID-SAPORINE CONJUGATE FOR THE TREATMENT OF CANCER

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003219277A1 (en) * 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129144B2 (en) 2008-03-12 2021-09-21 Panasonic Intellectual Property Corporation Of America Integrated circuit
US8942277B2 (en) 2008-03-12 2015-01-27 Panasonic Intellectual Property Corporation Of America Wireless communication apparatus and wireless communication method
US9276706B2 (en) 2008-03-12 2016-03-01 Panasonic Intellectual Property Corporation Of America Communication apparatus and communication method
US8532164B2 (en) 2008-03-12 2013-09-10 Panasonic Corporation Wireless communication apparatus, wireless communication system, and wireless communication method
US10206198B2 (en) 2008-03-12 2019-02-12 Panasonic Intellectual Property Corporation Of America Communication apparatus and communication method
US10694506B2 (en) 2008-03-12 2020-06-23 Panasonic Intellectual Property Corporation Of America Integrated circuit
JP2017529870A (ja) * 2014-07-22 2017-10-12 オルム セラピューティクス インコーポレイテッドＯｒｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 完全型免疫グロブリン形態の細胞質浸透能を有する抗体を利用して細胞内活性化されたｒａｓを抑制する方法及びその利用
US10844136B2 (en) 2014-07-22 2020-11-24 Orum Therapeutics Inc. Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same
US10851177B2 (en) 2014-07-22 2020-12-01 Orum Therapeutics Inc. Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof
US11155641B2 (en) 2016-05-27 2021-10-26 Orum Therapeutics Inc. Cytosol-penetrating antibody and use thereof
US10787487B2 (en) 2018-06-21 2020-09-29 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies
JP2023525164A (ja) * 2020-05-12 2023-06-14 オックスフォード・ユニバーシティ・イノベイション・リミテッド 標的特異的分解剤及びそれらの医学的使用
JP7779861B2 (ja) 2020-05-12 2025-12-03 オックスフォード・ユニバーシティ・イノベイション・リミテッド 標的特異的分解剤及びそれらの医学的使用

Also Published As

Publication number Publication date
WO2004046188A3 (en) 2004-09-16
EP1565495A2 (en) 2005-08-24
US20050288492A1 (en) 2005-12-29
AU2003282247A1 (en) 2004-06-15
CA2506128A1 (en) 2004-06-03
WO2004046188A2 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
CN108884160B (zh) 抗ror1抗体
JP2006523086A (ja) 発癌性形態のｒａｓに対する細胞内発現抗体
JP2025118590A (ja) 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
JP7360720B2 (ja) 抗ｐｄ―ｌ１抗体およびその用途
JP2023515505A (ja) Ｗｎｔスーパーアゴニスト
US20100240100A1 (en) Human antibodies that have mn binding and cell adhesion-neutralizing activity
JP2005168489A (ja) 癌マーカー用生物合成結合蛋白質
WO2022117040A1 (zh) 抗人b7-h3抗体及其应用
JP2023134497A (ja) Ｍｕｃ１７及びｃｄ３に向けられる二重特異性抗体コンストラクト
US9631020B2 (en) Anti-c-Met antibody having HGF activity and use thereof
US20050288492A1 (en) Anti-activated RAS antibodies
JP2004500828A (ja) Ｍｕｃｉｎ−１特異的結合メンバー及びその使用方法
CN112442122B (zh) 阻断型pd-1纳米抗体及其编码序列和用途
WO2021155635A1 (zh) 抗cd3和cd123双特异性抗体及其用途
KR20230154235A (ko) NKp46에 대한 항체 및 이의 적용
CN118215682A (zh) 抗转铁蛋白受体抗体及其用途
CN110885377B (zh) 抗cd47/vegf双特异性抗体及其应用
CN102380097A (zh) 用于治疗动脉粥样硬化的肽基被动免疫接种疗法
WO2025098364A1 (zh) 靶向人源pd-l1的全人源抗体
WO2021244587A1 (zh) 一种抗PD-L1/TGF-β融合蛋白
CN116023491A (zh) 抗cd26抗体及其应用
WO2004046187A2 (en) Antibodies for in vitro use
WO2022268168A1 (zh) 靶向lag-3和pd-l1的新型双特异抗体及其应用
WO2024173565A2 (en) Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants
TW202542202A (zh) 抗體、抗原結合片段及其醫療用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061012

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20061228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061228